uploads/2018/08/Activase.png

How Roche’s Activase, Mircera, and Epogin Look in August

By

Updated

Activase/TNKase’s revenue trends

Roche’s (RHHBY) Activase/TNKase reported revenues of 652.0 million Swiss francs in the first half compared to 613.0 million Swiss francs in the first half of 2017, reflecting ~9% YoY (year-over-year) growth at constant exchange rates (or CER).

In the second quarter, Activase/TNKase generated revenues of 329.0 million Swiss francs, which reflected ~10% YoY growth at CER. In the US market, Activase/TNKase generated second-quarter revenues of 315.0 million Swiss francs, which reflected ~11% YoY growth at CER. Activase/TNKase (Tenecteplase) is used for decreasing mortality associated with acute myocardial infarction.

Article continues below advertisement

Mircera’s revenue trends

Mircera reported revenues of 248.0 million Swiss francs in the first half compared to 236.0 million Swiss francs in the first half of 2017, reflecting ~4% YoY growth at CER. In the first half, in Europe, Japan, and international markets, Mircera reported revenues of 39.0 million Swiss francs, 95.0 million Swiss francs, and 144.0 million Swiss francs, respectively, reflecting an ~17% YoY decline, a 3% YoY decline, and 22% YoY growth at CER.

In the second quarter, Mircera generated revenues of 128 Swiss francs, which reflected ~4% YoY growth at CER. Mircera (epoetin beta and methoxy polyethylene glycol) is used for the treatment of individuals with anemia with chronic kidney disease.

NeoRecormon/Epogin’s revenue trends

NeoRecormon/Epogin generated revenues of 149.0 million Swiss francs in the first half compared to 156.0 million Swiss francs in the first half of 2017, reflecting ~8% YoY growth at CER.

In the Europe, Japan, and International markets, NeoRecormon/Epogin generated first-half revenues of 57.0 million Swiss francs, 18.0 million Swiss francs, and 74.0 million Swiss francs, respectively, reflecting an ~17% decline, an ~16% decline, and 3% growth on a YoY basis at CER.

In the second quarter, NeoRecormon/Epogin generated revenues of 79.0 million Swiss francs, reflecting an ~4% YoY decline at CER.

Amgen’s (AMGN) Aranesp and Epogen are also widely used drugs for the treatment of anemia with chronic kidney disease. Aranesp and Epogen generated revenues of $472.0 million and $250.0 million, respectively, in the second quarter.

Advertisement

More From Market Realist